RxDoctor Payments Data

Daniel Ring, MD

Dermatology · Chesterfield, MONPI 1790778249

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 910 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.

$18,771in general payments, 2019–2025

Across 910 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$981
  • Lilly USA, LLC$944
  • E.r. Squibb & Sons, L.L.C.$894
  • plus $10K from 38 others
$4,574in research payments, 2019–2025

Across 1 payment — averaging $4574.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$5K

What the payments were for

  • Food & beverage$18,33498%
  • Education$4362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,771 in reported general payments places this provider in the 85th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$237,656
Medicare patients
749
Services billed
3,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$49,579
Fluorouracil85$5,948
Metronidazole71$4,219
Clobetasol Propionate81$3,414
Doxycycline Hyclate83$1,540
Calcipotriene11$1,182
ValacyclovirValacyclovir Hcl40$848
Triamcinolone Acetonide131$726
Clindamycin Phosphate23$640
Ciclopirox18$563
Minocycline Hcl32$493
Ketoconazole37$483
Cephalexin20$404
Fluocinonide11$332
Mupirocin46$269

Paid to pharmacies, not to this prescriber.

Other dermatology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →